Effects of tauroursodeoxycholate solutions on cyclosporin A bioavailability in rats.

Cyclosporin A (CsA) exhibits poor bioavailability after oral administration of Sandimmune, with wide intra- and interindividual variations. Our study sought to determine the effect of the coadministration of CsA standard oily formulation and tauroursodeoxycholate (TUDC) and that of an aqueous micellar solution containing TUDC, monoolein, and CsA in promoting and regulating CsA bioavailability in the rat Pharmacokinetic parameters of CsA were determined in fasted rats after either an intravenous administration (5 mg/kg) or a single oral CsA dose of 10 mg/kg. Compared with oral Sandimmune, the CsA micellar solution significantly improved the CsA bioavailability by 160% and decreased the interindividual variability in bioavailability expressed as percent coefficient of variation from 32% to 15%. The concentration-time profile was modified with a 3.5-fold increase in C(max), a reduction of t(max), and an increased trough concentration. Bioavailability slightly improved in rats receiving standard oily solution plus concomitant TUDC, although not significantly. Data indicate that the structure of the CsA carriers greatly affect drug bioavailability and that aqueous micellar solutions of CsA-TUDC-monoolein constitute efficient vehicles, thus providing for CsA high absorption with low variability.

[1]  G. Alexander,et al.  Absorption of cyclosporin from conventional and new microemulsion oral formulations in liver transplant recipients with external biliary diversion. , 1995, British journal of clinical pharmacology.

[2]  D. Keppler,et al.  Cholestasis caused by inhibition of the adenosine triphosphate-dependent bile salt transport in rat liver. , 1994, Gastroenterology.

[3]  J. Tredger,et al.  Variable effect of ursodeoxycholic acid on cyclosporin absorption after orthotopic liver transplantation , 1994, Transplant international : official journal of the European Society for Organ Transplantation.

[4]  P. Queneau,et al.  Hepatoprotection by hydrophilic bile salts. , 1994, Journal of hepatology.

[5]  P. Bertault-peres,et al.  DIMINUTION OF AN ACUTE CYCLOSPORIN‐INDUCED CHOLESTASIS BY TAUROURSODEOXYCHOLATE IN THE RAT , 1993, Transplantation.

[6]  B. Kahan,et al.  Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation , 1993, Clinical pharmacology and therapeutics.

[7]  C. Figarella,et al.  Effects of ursodeoxycholic acid on liver function in patients with cystic fibrosis and chronic cholestasis. , 1992, The Journal of pediatrics.

[8]  T. Kissel,et al.  Enhancement of the oral absorption of cyclosporin in man. , 1992, British journal of clinical pharmacology.

[9]  B. Balkau,et al.  A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. , 1991, The New England journal of medicine.

[10]  B. Kommerell,et al.  Effective treatment of cyclosporine-induced cholestasis in heart-transplanted patients treated with ursodeoxycholic acid. , 1991, Transplantation.

[11]  P. Bertault-peres,et al.  Pharmacokinetics of cyclosporine A in bilateral lung transplantation candidates with cystic fibrosis. , 1990, Transplantation proceedings.

[12]  L. Benet,et al.  Effect of Food on the Pharmacokinetics of Cyclosporine in Healthy Subjects Following Oral and Intravenous Administration , 1990, Journal of clinical pharmacology.

[13]  R. Dahlqvist,et al.  The effect of food and bile acid administration on the relative bioavailability of cyclosporin. , 1990, British journal of clinical pharmacology.

[14]  J. Emond,et al.  Small-bowel length and the dose of cyclosporine in children after liver transplantation. , 1990, The New England journal of medicine.

[15]  K. Hübner,et al.  Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial. , 1989, Gastroenterology.

[16]  L. Benet,et al.  Absorption kinetics of cyclosporine in healthy volunteers. , 1989, Biopharmaceutics & drug disposition.

[17]  B. Shneider,et al.  The effect of biliary enteroenterostomy on the pharmacokinetics of enterally administered cyclosporine in rats , 1989, Hepatology.

[18]  J. Tredger,et al.  Cyclosporin A pharmacokinetics in liver transplant recipients in relation to biliary T-tube clamping and liver dysfunction. , 1989, Gut.

[19]  I. Sketris,et al.  Cyclosporine Absorption in Two Patients with Short-Bowel Syndrome , 1988, Drug intelligence & clinical pharmacy.

[20]  D. V. van Thiel,et al.  Effect of bile on cyclosporin absorption in liver transplant patients. , 1988, British journal of clinical pharmacology.

[21]  T. Starzl,et al.  Effect of liver dysfunction on cyclosporine pharmacokinetics. , 1987, Transplantation proceedings.

[22]  D. V. van Thiel,et al.  Role of bile and bile salts on cyclosporine absorption in dogs. , 1987, Transplantation proceedings.

[23]  T. Starzl,et al.  Cyclosporine Absorption Following Orthotopic Liver Transplantation , 1986, Journal of clinical pharmacology.

[24]  R. Venkataramanan,et al.  Clinical Pharmacokinetics of Cyclosporin , 1986, Clinical pharmacokinetics.

[25]  M. Lemaire,et al.  Apparent dose-dependent oral absorption of cyclosporin A in rats. , 1984, Biopharmaceutics & drug disposition.

[26]  P. Lazzeretti,et al.  First‐order polarization propagator approach to nuclear spin–spin coupling tensors in SiH4 and AlH−4 , 1984 .

[27]  M. Lindheimer,et al.  Self-diffusion study of bile salt-monoolein micelles determination of the intermicellar bile salt concentration , 1983 .

[28]  M. Lindheimer,et al.  Mixed micelle properties and intestinal cholesterol uptake. , 1982, Biochimie.

[29]  M. Armstrong,et al.  Thermodynamic and molecular basis for dissimilar cholesterol-solubilizing capacities by micellar solutions of bile salts: cases of sodium chenodeoxycholate and sodium ursodeoxycholate and their glycine and taurine conjugates. , 1981, Biochemistry.

[30]  D. Small,et al.  The physical chemistry of cholesterol solubility in bile. Relationship to gallstone formation and dissolution in man. , 1978, The Journal of clinical investigation.

[31]  J. Dietschy,et al.  The mechanism whereby bile acid micelles increase the rate of fatty acid and cholesterol uptake into the intestinal mucosal cell. , 1976, The Journal of clinical investigation.